Literature DB >> 16513682

Epigenetic alterations in RASSF1A in human aberrant crypt foci.

Emily J Greenspan1, Melissa A Jablonski, Thiruchandurai V Rajan, Joel Levine, Glenn S Belinsky, Daniel W Rosenberg.   

Abstract

CpG island methylation (CIM) is an epigenetic mechanism for transcriptional silencing that occurs at various stages of colon tumorigenesis. CIM has been found in serrated adenomas and hyperplastic polyps. There is also evidence for hypermethylation in aberrant crypt foci (ACF) that are found in resected colons from cancer patients. Our study addresses promoter methylation of a tumor suppressor gene, RASSF1A, within the colonic epithelium of subjects undergoing screening colonoscopies in the absence of synchronous tumors. Patients included in this study were at elevated risk for colorectal cancer (CRC) based on family history, but without a previously occurring or synchronous colon carcinoma. ACF were identified using close-focus magnifying chromendoscopy and collected by biopsy in situ. We isolated ACF and adjacent normal colonic epithelium by laser capture microdissection (LCM) and studied methylation of the RASSF1A promoter region in ACF and in adjacent normal mucosa. Expression of RASSF1A was verified using quantitative real-time polymerase chain reaction (QRT-PCR). We found that 8.6% (3 out of 35) of ACF had K-ras mutations and 24% (6 out of 25) had RASSF1A hypermethylation. Our results demonstrate that RASSF1A hypermethylation and K-ras mutations are not mutually exclusive and are present in patients at elevated risk of CRC. Importantly, CIM of RASSF1A is an early epigenetic aberration, occurring in the absence of synchronous colon tumors and is not accompanied by field effects into the surrounding epithelium.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513682      PMCID: PMC3117759          DOI: 10.1093/carcin/bgi373

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  30 in total

1.  RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer.

Authors:  Jie Li; Zhongqiu Zhang; Zunyan Dai; Anthony P Popkie; Christoph Plass; Carl Morrison; Yian Wang; Ming You
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

2.  Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.

Authors:  Carla Oliveira; Sérgia Velho; Enric Domingo; Ana Preto; Robert M W Hofstra; Richard Hamelin; Hiroyuki Yamamoto; Raquel Seruca; Simo Schwartz
Journal:  Oncogene       Date:  2005-11-17       Impact factor: 9.867

3.  CpG island methylation in aberrant crypt foci of the colorectum.

Authors:  Annie On-On Chan; Russell R Broaddus; Patrick S Houlihan; Jean-Pierre J Issa; Stanley R Hamilton; Asif Rashid
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 4.  A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.

Authors:  Boudewijn J M Braakhuis; Maarten P Tabor; J Alain Kummer; C René Leemans; Ruud H Brakenhoff
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

5.  CpG island methylation in colorectal adenomas.

Authors:  A Rashid; L Shen; J S Morris; J P Issa; S R Hamilton
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

6.  K-ras mutations and RASSF1A promoter methylation in colorectal cancer.

Authors:  Manon van Engeland; Guido M J M Roemen; Mirian Brink; Marco M M Pachen; Matty P Weijenberg; Adriaan P de Bruïne; Jan-Willem Arends; Piet A van den Brandt; Anton F P M de Goeij; James G Herman
Journal:  Oncogene       Date:  2002-05-23       Impact factor: 9.867

7.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.

Authors:  R Dammann; C Li; J H Yoon; P L Chin; S Bates; G P Pfeifer
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

8.  The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation.

Authors:  Latha Shivakumar; John Minna; Toshiyuki Sakamaki; Richard Pestell; Michael A White
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

9.  Frequent CpG island methylation in serrated adenomas of the colorectum.

Authors:  Seun-Ja Park; Asif Rashid; Jae-Hyuk Lee; Sang Geol Kim; Stanley R Hamilton; Tsung-Teh Wu
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

Review 10.  Emerging concepts in colorectal neoplasia.

Authors:  Jeremy R Jass; Vicki L J Whitehall; Joanne Young; Barbara A Leggett
Journal:  Gastroenterology       Date:  2002-09       Impact factor: 22.682

View more
  13 in total

1.  Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues.

Authors:  Dimo Dietrich; Ralf Lesche; Reimo Tetzner; Manuel Krispin; Jörn Dietrich; Wolfgang Haedicke; Matthias Schuster; Glen Kristiansen
Journal:  J Histochem Cytochem       Date:  2009-01-19       Impact factor: 2.479

2.  HD chromoendoscopy coupled with DNA mass spectrometry profiling identifies somatic mutations in microdissected human proximal aberrant crypt foci.

Authors:  David A Drew; Thomas J Devers; Michael J O'Brien; Nicole A Horelik; Joel Levine; Daniel W Rosenberg
Journal:  Mol Cancer Res       Date:  2014-03-20       Impact factor: 5.852

Review 3.  The Role of Stem Cell DNA Methylation in Colorectal Carcinogenesis.

Authors:  Lele Song; Yuemin Li
Journal:  Stem Cell Rev Rep       Date:  2016-10       Impact factor: 5.739

4.  Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways.

Authors:  A R Dallosso; B Øster; A Greenhough; K Thorsen; T J Curry; C Owen; A L Hancock; M Szemes; C Paraskeva; M Frank; C L Andersen; K Malik
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

Review 5.  Epidemiology of colonic aberrant crypt foci: review and analysis of existing studies.

Authors:  Richard G Stevens; Helen Swede; Daniel W Rosenberg
Journal:  Cancer Lett       Date:  2006-12-19       Impact factor: 8.679

Review 6.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.

Authors:  Hariharan Easwaran; Hsing-Chen Tsai; Stephen B Baylin
Journal:  Mol Cell       Date:  2014-06-05       Impact factor: 17.970

7.  Epigenetic analysis of laser capture microdissected fetal epithelia.

Authors:  Ratnam S Seelan; Dennis R Warner; Partha M Mukhopadhyay; Sarah A Andres; Irina A Smolenkova; James L Wittliff; M Michele Pisano; Robert M Greene
Journal:  Anal Biochem       Date:  2013-07-30       Impact factor: 3.365

8.  Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors.

Authors:  Giorgio Malpeli; Eliana Amato; Mario Dandrea; Caterina Fumagalli; Valentina Debattisti; Letizia Boninsegna; Giuseppe Pelosi; Massimo Falconi; Aldo Scarpa
Journal:  BMC Cancer       Date:  2011-08-12       Impact factor: 4.430

9.  Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer.

Authors:  Victoria Gonzalo; Juan José Lozano; Jenifer Muñoz; Francesc Balaguer; Maria Pellisé; Cristina Rodríguez de Miguel; Montserrat Andreu; Rodrigo Jover; Xavier Llor; M Dolores Giráldez; Teresa Ocaña; Anna Serradesanferm; Virginia Alonso-Espinaco; Mireya Jimeno; Miriam Cuatrecasas; Oriol Sendino; Sergi Castellví-Bel; Antoni Castells
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

Review 10.  Epigenetically inactivated RASSF1A as a tumor biomarker.

Authors:  Dora Raos; Monika Ulamec; Ana Katusic Bojanac; Floriana Bulic-Jakus; Davor Jezek; Nino Sincic
Journal:  Bosn J Basic Med Sci       Date:  2021-08-01       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.